Literature DB >> 11057510

High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1.

D Rey1, J Vidinic-Moularde, P Meyer, C Schmitt, S Fritsch, J M Lang, F Stoll-Keller.   

Abstract

The prevalence of GB virus C (GBV-C)/ hepatitis G virus (HGV) RNA and antibodies to the structural E2 protein was investigated in a cohort of HIV-1 infected patients. Of 346 individuals, RNA was detected in 143 and E2 antibodies were detected in 73, for an overall prevalence of 62.4%. Intravenous drug use and homosexuality were identified as major transmission risk factors. GBV-C/HGV RNA prevalence was associated with hepatitis B coinfection, whereas antibodies to E2 were associated with older age and lower CD4+ cell counts. GBV-C/HGV infection was frequent in this group of HIV-infected patients and was associated with older age, lower CD4 + cell counts, and the presence of hepatitis B surface antigen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11057510     DOI: 10.1007/s100960000352

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

Authors:  Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer
Journal:  J Infect Dis       Date:  2012-03-20       Impact factor: 5.226

2.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

3.  Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

Authors:  James H McLinden; Thomas M Kaufman; Jinhua Xiang; Qing Chang; Donna Klinzman; Alfred M Engel; Georg Hess; Urban Schmidt; Michael Houghton; Jack T Stapleton
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

4.  Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients.

Authors:  Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer
Journal:  J Infect Dis       Date:  2014-11-25       Impact factor: 5.226

5.  Hepatitis G virus infection in Egyptian children with chronic renal failure (single centre study).

Authors:  Ayman Mohammad Hammad; Mohammad Hosam El Deen Zaghloul
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-12-16       Impact factor: 3.944

Review 6.  Coinfecting viruses as determinants of HIV disease.

Authors:  Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

7.  GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

8.  Bayesian analysis and classification of two enzyme-linked immunosorbent assay tests without a gold standard.

Authors:  Jingyang Zhang; Kathryn Chaloner; James H McLinden; Jack T Stapleton
Journal:  Stat Med       Date:  2013-04-17       Impact factor: 2.373

9.  Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.

Authors:  James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

10.  GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Alan L Landay; Ernest T Chivero; Jack T Stapleton
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.